Scopus BioPharma’s Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
September 28 2021 - 9:15AM
Scopus BioPharma Inc. (Nasdaq:
“SCPS”), a clinical-stage biopharmaceutical company
developing transformational therapeutics for serious diseases with
significant unmet medical need, announced today that Duet
Therapeutics, a wholly-owned subsidiary of Scopus, will release
scientific data during the 17th Annual Meeting of the
Oligonucleotide Therapeutics Society. The meeting will conclude on
Wednesday, September 29, 2021.
Alan Horsager, Ph.D., President and Chief
Executive Officer of Duet and President — Immuno-Oncology of
Scopus, will present DUET-01: Bispecific Oligonucleotide Targeting
TLR9 and STAT3 Signaling for B Cell Lymphoma Immunotherapy as part
of Session VIII: Oligonucleotide Preclinical I.
Dr. Horsager has also presented Bifunctional
Oligonucleotides for Systemic Treatment of Immunologically Cold
Solid Tumors as an Industry Talk.
Duet has also released a video depicting the mechanism of action
for its proprietary CpG-STAT3 inhibitors, which can be viewed here,
to coincide with Duet’s presentations at the OTS Meeting.
About the Duet
Platform
Duet Therapeutics integrates the immunotherapy
assets of Scopus and Olimmune, creating the Duet Platform. Olimmune
was acquired by Scopus in June 2021. Duet is a wholly-owned
subsidiary of Scopus.
The Duet Platform is comprised of three
distinctive, complementary CpG-STAT3 inhibitors:
• RNA silencing |
CpG-STAT3siRNA |
(“DUET-01”) |
• Antisense |
CpG-STAT3ASO |
(“DUET-02”) |
• DNA-binding inhibitor |
CpG-STAT3decoy |
(“DUET-03”) |
DUET-01 is in a Phase 1 clinical trial, as a
monotherapy, for B-cell non-Hodgkin lymphoma. Duet expects to file
two INDs for DUET-02 in Q4 2022 in genitourinary and head &
neck cancers, with clinical Phase 1 trials beginning in Q1 2023 in
the United States. Duet is also evaluating combination therapies
with checkpoint inhibitors.
About Scopus BioPharma
Scopus BioPharma Inc., both directly and through
subsidiaries, is a clinical-stage biopharmaceutical company
developing transformational therapeutics for serious diseases with
significant unmet medical need. The company’s lead drug candidate
is a novel, targeted immuno-oncology RNA therapy for the treatment
of multiple cancers. This drug candidate is highly distinctive,
encompassing both RNA therapy and immunotherapy by synthetically
linking siRNA to an oligonucleotide TLR9 agonist, creating the
potential for targeted gene silencing with simultaneous TLR
stimulation and immune activation in the tumor microenvironment.
Additional STAT3-targeting immunotherapy drug candidates include
bifunctional antisense and DNA-binding inhibition therapies. In
addition, the company is developing additional drug candidates that
target the endocannabinoid system, including MRI-1867 for the
treatment systemic sclerosis. The company also seeks to identify
additional compelling technologies for potential acquisition,
in-licensing and/or other similar transactions. Receive updates by
following Scopus BioPharma on Twitter here.
Forward-Looking Statements
This press release may include forward-looking
statements that involve risks and uncertainties. Forward-looking
statements are statements that are not historical facts. Such
forward-looking statements are subject to risks (including those
set forth in the company’s Form 10-K for the fiscal year ended
December 31, 2020, as amended, filed with the U.S. Securities and
Exchange Commission (“SEC”)) and uncertainties which could cause
actual results to differ from the forward-looking statements. The
company expressly disclaims any obligations or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in the company’s
expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
Investors should realize that if our underlying assumptions for the
projections contained herein prove inaccurate or that known or
unknown risks or uncertainties materialize, actual results could
vary materially from our expectations and projections. Further,
there can be no assurance that the company will identify and/or
consummate any transaction relating to any additional
technologies.
Contacts
Rodd Leeds/David WaldmanCrescendo
Communications, LLCTel: (212) 671-1020Email:
SCPS@crescendo-ir.com
Hugh Burns/Delia Cannan/Nicholas LeasureReevemarkTel: (212)
433-4600Email: scopus@reevemark.com
Scopus BioPharma (NASDAQ:SCPS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scopus BioPharma (NASDAQ:SCPS)
Historical Stock Chart
From Jul 2023 to Jul 2024